Skip to main content

Paradigm Therapeutics to be honored with Partners in Progress Award

On Saturday, October 26, 2024, Paradigm Therapeutics will be honored with the Partners in Progress Award at the debra of America Benefit at SoFi Stadium in Los Angeles, CA. RSVP here! 

“I want to thank debra of America for selecting our Paradigm team to receive the Partners in Progress Award," shares Dr. Robert Ryan, Chief Executive Officer at Paradigm Therapeutics, Inc. “We have been working tirelessly to develop a therapy that can benefit all patients and to be recognized for our efforts is truly a distinct honor. This award is a tribute to our passionate team and our true reward will be when we make this therapy available to all patients.” 

Paradigm Therapeutics is a Charleston, South Carolina based biotechnology company founded by a passionate group of professionals looking to develop innovative therapies for people living with rare diseases. Their late-stage topical therapy, designated as ZorblisaTM (SD-101-6.0), is being developed as a chronic whole skin surface treatment for the cutaneous manifestations observed in patients across all subtypes of Epidermolysis Bullosa (EB), with the ability to initiate treatment beginning at birth. Their group has been involved with the EB Community for over 12 years with the goal to provide an effective whole skin surface treatment that could benefit patients with Simplex, Dystrophic and Junctional EB. 

Photo of Dr. Robert Ryan
Dr. Robert Ryan, Chief Executive Officer at Paradigm Therapeutics, Inc.

SD-101-6.0 has been assessed in Phase 2 and 3 studies in EB patients including pediatric patients (including neonates) through adults and is being developed to treat patients across all subtypes of EB. In addition, long term safety of the product has been assessed in EB patients, with average daily usage in excess of 2 years. 

“We are working diligently to work with regulators to make this therapy available for EB patients across all subtypes as quickly as possible, and we are honored to be recognized for our efforts,” shares Dr. Robert Ryan. “Our goal to have a therapy that can provide multiple clinical benefits to all EB patients is near and the support by the EB Community to make this happen has been tremendous and much appreciated.” 

debra of America is proud to partner with Paradigm Therapeutics to improve the quality of life of all those impacted by EB.